Hetero launches generic Lapatinib under the brand name HERTAB in India

HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy.

Hyderabad: Hetero, one of India's generic pharmaceutical companies and producer of anti-retroviral drugs, recently announced the launch of generic version of Lapatinib (250 mg) tablets in India.

The product is marketed and distributed under the brand name 'HERTAB' by Hetero Healthcare Ltd. It is made available in two SKUs, each consisting of 30 tablets and 150 tablets.

HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy.

Lapatinib is used in combination with other medication Capecitabine or Letrozole, which together, inhibit the growth of cancer cells in patients.

Hetero's business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for Research and Development, manufacturing and commercialization of a wide range of products.

Also Read: Hetero Labs Limited acquires Tarbis Farma in Spain